Vis enkel innførsel

dc.contributor.authorRiise, Jon
dc.contributor.authorMeyer, Saskia
dc.contributor.authorBlaas, Isaac
dc.contributor.authorChopra, Adity
dc.contributor.authorTran, Trung
dc.contributor.authorDelic-Sarac, Marina
dc.contributor.authorHestdalen, Malu Lian
dc.contributor.authorBrodin, Ellen Elisabeth
dc.contributor.authorRustad, Even Holth
dc.contributor.authorDai, Ke-Zheng
dc.contributor.authorVaage, John T.
dc.contributor.authorNissen-Meyer, Lise Sofie Haug
dc.contributor.authorSund, Fredrik
dc.contributor.authorWader, Karin Fahl
dc.contributor.authorBjørnevik, Anne Turid
dc.contributor.authorMeyer, Peter Albert
dc.contributor.authorNygaard, Gro Owren
dc.contributor.authorKönig, Marton
dc.contributor.authorSmeland, Sigbjørn
dc.contributor.authorLund-Johansen, Fridtjof
dc.contributor.authorOlweus, Johanna
dc.contributor.authorKolstad, Arne
dc.identifier.citationBritish Journal of Haematology. 2022, 197 (6), 697-708.en_US
dc.description.abstractB-cell depletion induced by anti-cluster of differentiation 20 (CD20) monoclonal antibody (mAb) therapy of patients with lymphoma is expected to impair humoral responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination, but effects on CD8 T-cell responses are unknown. Here, we investigated humoral and CD8 T-cell responses following two vaccinations in patients with lymphoma undergoing anti-CD20-mAb therapy as single agent or in combination with chemotherapy or other anti-neoplastic agents during the last 9 months prior to inclusion, and in healthy age-matched blood donors. Antibody measurements showed that seven of 110 patients had antibodies to the receptor-binding domain of the SARS-CoV-2 Spike protein 3–6 weeks after the second dose of vaccination. Peripheral blood CD8 T-cell responses against prevalent human leucocyte antigen (HLA) class I SARS-CoV-2 epitopes were determined by peptide-HLA multimer analysis. Strong CD8 T-cell responses were observed in samples from 20/29 patients (69%) and 12/16 (75%) controls, with similar median response magnitudes in the groups and some of the strongest responses observed in patients. We conclude that despite the absence of humoral immune responses in fully SARS-CoV-2-vaccinated, anti-CD20-treated patients with lymphoma, their CD8 T-cell responses reach similar frequencies and magnitudes as for controls. Patients with lymphoma on B-cell depleting therapies are thus likely to benefit from current coronavirus disease 2019 (COVID-19) vaccines, and development of vaccines aimed at eliciting T-cell responses to non-Spike epitopes might provide improved protection.en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.titleRituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccinationen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.source.journalBritish Journal of Haematologyen_US

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal